.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,372,995

« Back to Dashboard

Claims for Patent: 8,372,995

Title:Crystalline solid forms of tigecycline and methods of preparing same
Abstract: Crystalline solid forms of tigecycline, Form I, Form II, Form III, Form IV, and Form V, compositions comprising these crystalline solid forms, and processes for preparing these crystalline solid forms are described herein.
Inventor(s): Krishnan; Lalitha (Suffern, NY), Deshmukh; Subodh S. (White Plains, NY), Hadfield; Anthony (St. Petersburg, FL), Huang; W. James (Hillsborough, NJ), Ku; Mannching Sherry (Thiells, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:11/440,032
Patent Claims: 1. A Form I tigecycline having X-ray powder diffraction peaks at about 5.2.degree. 2.theta., about 8.3.degree. 2.theta., about 11.1.degree. 2.theta., and about 24.8.degree. 2.theta. and having a hot stage melting point onset temperature of about 170.degree. C. to about 172.degree. C.

2. A composition consisting essentially of Form I tigecycline having X-ray powder diffraction peaks at about 5.2.degree. 2.theta., about 8.3.degree. 2.theta., about 11.1.degree. 2.theta., and about 24.8.degree. 2.theta. and having a hot stage melting point onset temperature of about 170.degree. C. to about 172.degree. C.

3. A process for preparing Form I tigecycline comprising crystallizing tigecycline out of a solution to form a slurry, and filtering the slurry to isolate Form I tigecycline having X-ray powder diffraction peaks at about 5.2.degree. 2.theta., about 8.3.degree. 2.theta., about 11.1.degree. 2.theta., and about 24.8.degree. 2.theta. and having a hot stage melting point onset temperature of about 170.degree. C. to about 172.degree. C.

4. The process of claim 3 wherein the solution contains methylene chloride.

5. The process of claim 3 further comprising drying the solution prior to the crystallizing step.

6. The process of claim 3 further comprising stirring the slurry prior to the filtering step.

7. The process of claim 3 further comprising combining said Form I tigecycline with at least one pharmaceutically suitable carrier to form a pharmaceutical composition.

8. A pharmaceutical composition made by the process of claim 7.

9. The process of claim 7 further comprising lyophilizing said pharmaceutical composition.

10. A pharmaceutical composition made by the process of claim 9.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc